All Posts Tagged With: "GSK"
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish
We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological...
8Dec2011 | vitalstocks | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral
We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company...
30Nov2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic...
28Nov2011 | vitalstocks | 0 comments | Continued(THRX) Theravance Third Quarter Loss Deteriorates
Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research...
2Nov2011 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales
Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of...
2Nov2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(VVUS) Vivus’ Erectile Dysfunction Drug Presents Positive Data
Vivus Inc. (VVUS) recently presented positive data from a late-stage trial on its erectile dysfunction (ED) candidate, avanafil, at the 47th European Association for the Study of Diabetes Annual Meeting. The REVIEW-Diabetes study (TA-302), which enrolled 390 patients with type...
20Sep2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In...
1Sep2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic...
30Aug2011 | vitalstocks | 0 comments | Continued(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients...
22Aug2011 | vitalstocks | 0 comments | Continued(ONXX) Onyx Analyst Downgrades Shares to Underperform
We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved...
16Aug2011 | vitalstocks | 0 comments | Continued(VVUS) Vivus’ Loss Narrowed Due To Lower Spend
Vivus Inc. (VVUS) posted adjusted loss of 14 cents per share during the second quarter of fiscal 2011, in line with the Zacks Consensus Estimate. However, the loss was narrower than the year-ago loss of 27 cents per share. Lower operating expenses led to the narrower loss. The...
9Aug2011 | vitalstocks | 0 comments | Continued(VRX) Valeant Pharmaceuticals International Beats Expectations – Ups View
Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents per share. Bottom-line...
8Aug2011 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek
Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus...
1Aug2011 | vitalstocks | 0 comments | Continued(RDY) Dr. Reddy’s Laboratories Earns FDA Approval for Generic
Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline...
14Jul2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Entangled in Legal Dispute
The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement case against Watson Pharma relating to Vyvanse. Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)...
8Jul2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications
Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline plc’s (GSK) Avodart, indicated for the treatment of benign prostatic...
29Jun2011 | vitalstocks | 0 comments | Continued(AMGN) Amgen Seeks Label Expansion
Amgen (AMGN) is looking to gain approval for additional indications of Xgeva. The company recently submitted a supplemental Biologics License Application (sBLA) seeking US Food and Drug Administration (FDA) approval for Xgeva (denosumab) for the reduction of the risk of developing...
29Jun2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference...
23Jun2011 | vitalstocks | 0 comments | Continued(VVUS) Vivus’ Erectile Dysfunction Drug on Track
Vivus Inc. (VVUS) recently reported positive results from a late-stage trial, REVIVE-RP (TA-303), on avanafil. The study evaluated the safety and efficacy of avanafil in the treatment of erectile dysfunction (ED) following bilateral, nerve-sparing, radical prostatectomy. The...
22Jun2011 | vitalstocks | 0 comments | Continued(PFE) Pfizer’s Chantix Could Increase Heart Risk
The US Food and Drug Administration (FDA) recently announced that Pfizer’s (PFE) smoking cessation aid Chantix (varenicline) could be linked with a small, increased risk of certain cardiovascular adverse events in patients with cardiovascular disease. The FDA’s announcement...
21Jun2011 | vitalstocks | 0 comments | Continued(EU) UCB Reports Data on Neupro
UCB (UCBJF) recently reported results from post hoc analyses of its restless legs syndrome (RLS) treatment Neupro (rotigotine). The data were presented at the International Congress of Parkinson’s disease and Movement disorders. RLS is a neurological disorder that causes an...
19Jun2011 | vitalstocks | 0 comments | Continued(THRX) Theravance Analyst Maintains Neutral on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus...
14Jun2011 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
14Jun2011 | vitalstocks | 0 comments | Continued(THRX) Theravance Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus...
14Jun2011 | vitalstocks | 0 comments | Continued(RDY) Dr. Reddy’s Laboratories Continues to Grow
Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses helped boost earnings. Year at a Glance The company reported revenues...
3Jun2011 | vitalstocks | 0 comments | Continued(CRM) Salesforce-Toyota Make Allies
Salesforce.com Inc. (CRM) recently announced a strategic alliance with the multinational automobile manufacturer Toyota Motors Corp. (TM). Under the terms of the agreement, the companies will jointly develop a private social networking service, Toyota Friend, for Toyota owners. The...
24May2011 | vitalstocks | 0 comments | Continued(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues
Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues...
18May2011 | vitalstocks | 0 comments | Continued